IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Not Yet Assigned

Norman Nash et al.

Serial No. 10/590,001

Art Unit:

Unknown

Filing Date of International Application:

November 4, 2004

Title: Use of the Lipoxin Receptor, FPRL1, as a Tool for Identifying Compounds

Effective in the Treatment of Pain and Inflammation

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SEQUENCE LISTING AND STATEMENT

Dear Sir:

Enclosed is the sequence listing for the above-identified patent application in computer readable form and a statement that the content of the sequence listing information is identical to the written sequence listing in the application. The undersigned hereby states that:

The content of the Sequence Listing recorded in the computer readable form, submitted herewith in accordance with 37 CFR §1.821(e), is identical to the written Sequence Listing in the international application.

Further, the enclosed CD-R is formatted for IBM-PC, the operating system is MS-Windows, and it contains one file, Acadia_65167_00023_final_sequence_list. TXT (ASCII), size 7KB, created on January 4, 2007.

Date: March 1, 2007

SQUIRE, SANDERS & DEMPSEY L.L.P.

One Maritime Plaza, Suite 300 San Francisco, California 94111

(415) 954-0200

Respectfully submitted,

Bernard F. Rose

Attorney for Applicants

Reg. No. 42,112